Eosinophil cationic protein: Is it useful in asthma? A systematic review  by Koh, Gerald C.-H. et al.
ARTICLE IN PRESS
Respiratory Medicine (2007) 101, 696–7050954-6111/$ - see fr
doi:10.1016/j.rmed.
$Statement of Co
Advisory Board for c
Sharpe & Dohme, Pﬁ
Corresponding au
E-mail address: cREVIEW
Eosinophil cationic protein: Is it useful in asthma?
A systematic review$
Gerald C.-H. Koha,, Lynette P.-C. Shekb, Daniel Y.-T. Gohb,
Hugo Van Beverb, David S.-Q. KohaaDepartment of Community, Occupational and Family Medicine, Yong Loo Lin School of Medicine,
National University of Singapore, Blk MD3, 16 Medical Drive, Singapore 117597, Singapore
bDepartment of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, National University Hospital,
5 Lower Kent Ridge Road, Singapore 119074, Singapore
Received 23 March 2006; accepted 14 August 2006KEYWORDS
Eosinophil cationic
protein;
ECP;
Asthma;
Biological marker;
Systematic reviewont matter & 2006
2006.08.012
nﬂict of Interest:
onsumer product
zer, Astra Zenec a
thor. Tel.: +65 651
ofkohch@nus.eduSummary
Introduction: Eosinophil cationic protein (ECP) has been widely investigated as a potential
biomarker of airway inﬂammation.
Method: A systematic review was performed using Medline with key terms eosinophil
cationic protein and asthma, limiting the search to titles or abstracts. Out of 688 potential
papers found, abstracts were reviewed based on the following criteria: (1) ECP was used as
a biological marker, (2) asthma was the index disease studied, (3) it was a controlled
clinical study and (4) ECP was assessed as a diagnostic, assessment or management tool.
One hundred and sixty-nine articles satisﬁed the selection criteria and their full-text
versions were reviewed. Only 53 papers were found to provide clinically useful
information.
Results: ECP has been measured in serum, plasma, sputum, saliva and broncho-alveolar
lavage ﬂuids but serum and sputum are the most established. Levels of ECP in normal and
asthmatic subjects in various body ﬂuids were identiﬁed. ECP correlates well with airway
inﬂammation but not airway hyper-responsiveness. It is raised in other atopic diseases and
hence is not diagnostic for asthma. However, it has been shown to be useful in assessing
asthma severity, compliance with anti-inﬂammatory asthma therapy and as a guide to
tailing down inhaled corticosteroid therapy. Although there is some evidence that ECP
levels are affected by age, smoking, circadian rhythm and seasonal variation, only smoking
appears to be of clinical signiﬁcance.Elsevier Ltd. All rights reserved.
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ECP: Is it useful in asthma? 697Discussion: Despite its limitations, ECP remains potentially useful in asthma management.
Future research on ECP should focus on using serial measurements and combining it with
other markers of asthma which may increase its clinical usefulness.
& 2006 Elsevier Ltd. All rights reserved.Contents
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To date, the assessment of asthma has been based mainly on
surrogate measures of airway inﬂammation such as airﬂow
limitation or reversibility using spirometry and related techni-
ques. Direct measurement of airway inﬂammation using
biological markers could potentially reﬁne asthma management
and this explains current research interest in exhaled nitric
oxide and eosinophil granule proteins in asthma.1 In recent
years, clinical research has suggested an emerging clinical
usefulness of eosinophil granule proteins in the assessment and
management of asthma, of which eosinophil cationic protein
(ECP) has been most widely characterized and researched. The
aim of this paper is to systematically review the current
evidence for the usefulness on ECP in asthma management and
suggest future areas for clinical research.
Methods
A systematic review was performed using the Quality of
Reporting of Meta-Analysis (QUORUM) Guidelines.2 A Medline
search using the key terms eosinophil cationic protein and
asthma was performed on 2 January 06, limiting the search
to title or abstract of papers and to humans only. A similar
search in major respiratory journals (i.e. Thorax, American
Journal of Respiratory and Critical Care Medicine, EuropeanRespiratory Journal, Respiratory Medicine and Journal of
Asthma) was also performed. Six hundred and eighty-eight
potential papers were found. The abstracts were then reviewed
based the following selection criteria: (1) ECP was used as a
biological marker (regardless of body ﬂuid sampled), (2) asthma
was the index disease studied (regardless of type of asthma),
(3) it was a controlled clinical study, (preferably but not limited
to randomized controlled trials) and (4) ECP was assessed as a
diagnostic, assessment or management tool. Only 169 articles
potentially satisﬁed the selection criteria. Full-text versions of
the papers were then obtained and reviewed. Relevant
references cited in the papers but not identiﬁed by the Medline
search were also obtained and reviewed. After full-text review,
only 53 papers were found to fulﬁll the selection criteria. A ﬂow
chart detailing the systematic review process is found in Fig. 1.
The results of the review are divided into two sections: the ﬁrst
part gives an overview of the biological properties and issues of
sampling ECP from various body ﬂuids and the second part
reports the uses and limitations of ECP in asthma management.
Results
Properties, characteristics and genetics of ECP
ECP is one of the four major cationic granule proteins
released by activated eosinophils [the other three being
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Abstracts of articles reviewed and the following inclusion 
criteria applied: 
1.  ECP was used as a biological marker (regardless of body 
fluid sampled). 
2.  Asthma was the index disease studied (regardless of type 
3.  It was a controlled clinical study. 
4.  ECP was assssed as a diagnostic, assessment or
management tool.  
Potential articles identified = 169 (519 were excluded) 
Full text articles were obtained and reviewed.  Relevant articles cited in 
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Results: 
 Potential articles identified = 688 
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references were also traced. 
Articles eventually included in systematic analysis = 53 
•
•
•
•
Figure 1 Stages of systematic analysis.
G.C.-H. Koh et al.698eosinophil protein X (EPX), eosinophil peroxidase (EPO) and
major basic protein (MBP)] and is presently the most widely
used clinical marker of eosinophil activity in asthma.3 ECP is
a single-chain, zinc-containing protein with a molecular
weight ranging from 16 to 22 kDa. The heterogeneity of the
molecule is partially due to differences in glycosylation of
three potential sites in its amino acid chain. The mechanism
of action of ECP is due to its cytotoxic capacity to create
pores in cell membranes.4 It has been shown to have
cytotoxic effects against bacteria, parasites, viruses and
respiratory epithelial cells.5–7 ECP also stimulates mucous
production in airways and histamine release by basophils
and mast cells in vitro.8–10 ECP is synthesized in eosinophil
progenitors in human bone marrow and stored in speciﬁc
granules in mature peripheral blood eosinophils. Triggers of
eosinophil release of ECP include immunoglobulin G com-
plexes and interleukin-5. In vitro, corticosteroids at
pharmacological doses appear to be unable to inhibit ECP
release from eosinophils. A more detailed account on the
properties and characteristics on ECP can be found in apaper by Venge et al.11 The gene that codes for ECP has been
located on chromosome 14q11.2 and three polymorphisms
have been identiﬁed by Noguchi et al.12 Although, no
relationship between ECP gene polymorphisms and asthma
was found in this study, serum ECP levels of persons with the
393T allele was lower than those with the 393C allele.
This may explain why serum ECP in some asthmatic patients
is not raised and the authors suggested that ECP measure-
ment in future asthma studies should include with genotyp-
ing for 393C/T polymorphism.ECP in body ﬂuids
ECP can be measured in many different body ﬂuids such as
serum, plasma, sputum, saliva, nasal lavage ﬂuid, broncho-
alveolar lavage ﬂuid and urine.3,11,13 The levels (normal and
asthmatic) and advantages and disadvantages of ECP
measurement in various body ﬂuids are detailed in Table 1.
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Table 1 Levels (normal and asthmatic), advantages and disadvantages of ECP measurement in various body ﬂuids.
Body ﬂuid Range of ECP levels (mg/L) Advantages Disadvantages
Normal Asthmatics
Serum11,13,14 2–20 420 Reﬂects propensity of
activated eosinophils to
release granule proteins
Blood must be collected
under tightly controlled and
standardized conditions
Plasma11,14 5–10 times lower than in serum Reﬂects true levels of ECP in
blood
Low levels are found because
EDTA inactivates ex-vivo
release of ECP
Sputum15–17 20–1280 76.8–32,000 High levels of ECP found  Requires induction of
sputum with nebulized
saline in non-productive
asthmatics
 There is wide overlap in
range of normal and
asthmatics
Saliva17 250–450 450–850  High levels of ECP found
 Easy and painless
collection process
Insufﬁcient research to
support its repeatability and
clinical utility
Nasal lavage
ﬂuid20–23
0–60 90–120 Painless but uncomfortable
collection process
 Difﬁcult to obtain samples
 Does not correlate well
with asthma
Broncho-
alveolar lavage
ﬂuid24,25
1–3 5–100 Moderate levels of ECP found Difﬁcult to obtain samples
Urine3,13,20 — — — Not useful. Urine eosinophil
protein X (EPX)/urine
creatinine ratio is more
useful. However, urinary EPX
is not widely used in asthma
research
Expressed as mg of ECP per g of protein.21
ECP: Is it useful in asthma? 699Serum and plasma ECP
The levels of ECP in serum is often ﬁve to ten times of those
in plasma because eosinophils in blood containing EDTA are
inactivated and do not continue their extracellular release
of ECP ex vivo.14 Hence, serum ECP levels reﬂect circulating
ECP and the propensity of active eosinophils to release ECP
ex vivo, which may explain why the clinical information
obtained using serum ECP have been found to be more
clinically useful than plasma ECP.11 ECP secretion in blood
samples can also increase by two to four times at 37 1C
relative to 22 1C when stored for an hour.14 Therefore, serum
sampling of ECP should be standardized as far as possible
because levels can vary depending on the storage time and
ambient temperature. The serum ECP level for both non-
atopic adults and children is less than 20 mg/L.13Sputum ECP
ECP is also present in the sputum. The median range of ECP
in sputum of non-asthmatics is about 200–350 mg/L, which ishigher than serum levels. A major challenge with sputum
measurement of ECP is that it has to be induced in non-
productive subjects with nebulized saline. Immediate
mucous and cell dispersion and cationic detergent addition
are needed for sputum to avoid ECP destruction or variable
attachment to test-tube walls and mucus. There is wide
overlap between reported values of ECP in normal subjects
which is likely due to the different reported methods of
analysis.15,16 Standardization of sputum ECP analysis is
needed before it is used more widely and important aspects
of this issue are well discussed in a recent paper by a sputum
analysis working group led by Kelly et al.17Salivary ECP
ECP has also been measured in saliva in adults and has been
found to correlate with asthma severity.18 Saliva ECP ranges
from 250 to 500 mg/L and levels were associated with
presumed activity of disease as recorded by alteration of
taken dose of inhaled corticosteroids (ICS). The reason why
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G.C.-H. Koh et al.700levels of ECP in sputum and saliva are 10 times higher than
serum is unclear. However, Schmekel et al.18 postulated that
sputum and saliva ECP reﬂected a pathophysiological
consequence of eosinophils present in the whole extent of
the airways and oral mucosa. Another possible reason is that
circulating eosinophils in blood retain their granule contents
until they reach diseased tissue, a hypothesis supported by a
recent study by Malm-Erjefalt et al.19 The measurement of
ECP in saliva is not well established and needs standardiza-
tion before it becomes an accepted biological medium of
assaying ECP in asthmatics.
ECP in nasal and broncho-alveolar ﬂuid
ECP can also be found in nasal20–23 and broncho-alveolar lavage
ﬂuids.24,25 However, the collection of these ﬂuids by nasal and
broncho-alveolar lavage is highly invasive and unlikely to enter
mainstream clinical use. Moreover, the measurement of ECP in
nasal and broncho-alveolar ﬂuid is not well standardized in
terms of dilution frequency and internal standards.24 Nasal
lavage ECP was previously found to poorly correlate with
asthma severity, although a recent study showed nasal lavage
ECP correlated with spirometric parameters.20,21
ECP in urine
Urinary ECP has found to be inferior to urinary EPX [also
known as eosinophil-derived neurotoxin (EDN)] as a marker
of eosinophil turnover and activity in asthma.3,13,20 Hence,
ECP in urine is not useful as a marker of asthma severity.
Clinical signiﬁcance of ECP in asthma
ECP and airway inﬂammation
Numerous studies have shown that ECP correlates well with
airway inﬂammation in asthma. Serum ECP was found to
directly correlate with activated eosinophils in bronchial
mucosa biopsied from adult asthmatic patients.26 Serum ECP
has also been found to be a more sensitive marker of asthma
severity than peripheral blood eosinophil counts in acute
exacerbations in children. In this study that compared serum
ECP and peripheral blood eosinophil count in 46 asthmatic
children, the ratio of ECP to eosinophil count was
signiﬁcantly greater during acute exacerbation than during
clinical remission [0.10470.049 versus 0.8470.041 (mg/L),
Po0.05].27 The authors hypothesized that eosinophils
released ECP preferentially during acute exacerbations than
during clinical remission.
Sputum ECP has been found to be better than sputum
eosinophils in characterizing oral corticosteroid dependent
asthmatics with recent exacerbations.28 In a study that
compared serum ECP and sputum ECP with asthma severity
using symptom scoring, sputum eosinophils and spirometry
(FEV1 and FEV1/VC), sputum ECP was found to be a more
sensitive marker of airway inﬂammation and asthma
severity than serum ECP.15
Serum ECP rises during asthma exacerbations caused by
upper respiratory infections.29 However, a study between
adult asthmatics experiencing exacerbations caused by
para-inﬂuenza virus 3 (PIV3) and non-PIV3-induced exacer-
bations found no signiﬁcant difference in their sputum ECP
levels.30 Another study found that serum ECP was raised in
children with asthma but not in infants with respiratorysyncytial virus (RSV) bronchiolitis.31 These studies suggest
that ECP levels are raised in virus-induced airway inﬂamma-
tion in asthma but are not affected by the type of virus
triggering asthma nor raised in bronchiolitis.
ECP and airway hyper-responsiveness
Although ECP correlates with airway inﬂammation, studies
in primates have found no correlation between ECP and
airway hyper-responsiveness.32 In a population-based study
on atopy of 1189 persons in Denmark, there was no
association between serum ECP and bronchial hyper-
reactivity as measured with methacholine challenge tests.33
Similar ﬁndings have been found in other studies on
asthma.15,34–37 The reason is probably because ECP is not
signiﬁcantly related to the release of bronchoactive
chemical mediators that increase the responsiveness of
airway smooth muscle. In contrast, MBP which is another
major cationic protein of eosinophil granules, has been
found to induce airway constriction and hyper-responsive-
ness in primates.32
ECP as an asthma marker
ECP as a diagnostic tool
There is strong evidence that sputum ECP is raised in
asthmatics, both in children and adults, and is increased in
classic asthma, cough-variant asthma and occupational
asthma.35,36,38–40 However, ECP is also raised in other atopic
diseases like allergic rhinitis and in pre-school children with
recurrent wheezing.41–43 ECP is also elevated in conditions
that are not associated with eosinophil inﬂammation or
atopy. For example, ECP in nasal lavage ﬂuid is also
associated with rhinovirus infections and bacterial sinusi-
tis.22,44 Hence, ECP is not a useful diagnostic marker for
asthma because of its poor speciﬁcity.45 It is worth noting
that serum ECP is poorly associated with exercise-induced
asthma, atopic eczema and food allergies.46–48 In allergic
rhinitis, nasal lavage ECP has been found to increase with
nasal allergen challenge 23 and seasonal allergen exposure 41
but reduced by immunotherapy.42,49
ECP as an assessment tool
There is now a good body of evidence that ECP can be used
to assess asthma severity. Serum ECP has been shown to
correlate with severity of asthma as classiﬁed by STEP
classiﬁcation of the National, Heart, Lung and Blood
Institute (NHLBI),50 FEV1,
50 FEV1/FVC,
50 peripheral blood
eosinophil count27 and severity of atopy based on wheal size
and number of positive prick tests.36 Sputum ECP has also
been found to correlate with asthma severity based on
NHLBI 51 and Japanese Society of Allergology criteria,16
PEFR,16,51 sputum eosinophils,16 need for oral corticosteroid
therapy28 and FEV1 in treated asthmatics.
51 Although, ECP
correlates with STEP classiﬁcation of asthma severity, there
is little difference in sputum ECP levels between mild
persistent and moderate asthmatic patients attending an
asthma clinic.51 Hence, ECP is useful mainly in distinguishing
between mild intermittent and severe asthmatics. This
ﬁnding is interesting in the light of a 10-year longitudinal
cohort study by de Marco et al. which found that patients
with intermittent or mild persistent asthma were a different
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ECP: Is it useful in asthma? 701phenotype from moderate and severe persistent asthma,
with the latter group characterized by high IgE levels,
persistent cough/mucus hypersecretion and early deteriora-
tion of lung function.52 A recent paper reported that serum
ECP was positively correlated to air-trapping in asthma as
measured by quantitative high-resolution computed tomo-
graphy (HRCT) which in turn, correlated with FEV1/FVC.
53
Serum ECP levels in an asthmatic child increases
signiﬁcantly during asthma exacerbation, from 27.47
11.5 mg/L at clinical remission to 41.7716.9 mg/L during
acute exacerbation.27 Sputum ECP is also signiﬁcantly
increased in adult oral corticosteroid-dependent asthmatics
who are uncontrolled and still experiencing acute exacer-
bations (mean ¼ 580 mg/L) compared to controlled oral
corticosteroid-dependent asthmatics (mean ¼ 194 mg/L).27
ECP as a management tool
A study by Prehn et al.54 using serum ECP to guide anti-
inﬂammatory treatment of asthma in children demonstrated
the usefulness of ECP in deciding when to tail down therapy.
Using a clinical algorithm, they titrated the dose of anti-
inﬂammatory drugs ICS based on serum ECP levels taken
monthly in 21 children over 12 months. Patients with
persistently raised ECP430 mg/L remained on high doses of
ICS (budesonide 400 mg bd), those with ECP between 15 and
30 mg/L were given budesonide 200 mg bd and those with ECP
o15 g/L received sodium cromoglycate only. Compliance
was counter-checked by weighing the metered dose inhalers
each month. During the study period, there was no asthma
attacks, need for emergency room treatment, hospital
admission or rescue treatment with oral steroid therapy in
all three groups of patients. This study supports strongly the
usefulness of ECP in guiding asthma therapy, considering
that 45% of adult asthmatics relapse after asthma exacer-
bation within 8 weeks.55 Prehn et al. also found that
patients who were non-compliant to ICS medication ex-
hibited an increase in serum ECP. ICS was more effective
than sodium cromoglycate in reducing serum ECP, improving
symptoms and lung function. Several other studies also
support the close relationship between ECP and use of
corticosteroids, suggesting that ECP can be used as a marker
of compliance to oral and ICS therapy.56–59 However, it
should be noted that the suppressive effect of ICS on ECP is
not sensitive enough to reﬂect small changes in doses.16,56
ECP correlates with other forms on anti-inﬂammatory agents
besides ICS and mast cell stabilizers. Sputum ECP declines with
leukotriene receptor antagonist (LTRA) therapy 60 but the
correlation is weaker when compared with ICS therapy.34,61,62
Anti-inﬂammatory therapy with tacrolimus in aspirin-induced
asthma is associated with declines in sputum ECP as well.63
Immunotherapy in asthmatic children is also associated with
decline in sputum ECP levels.64 However, ECP is not affected by
H1 anti-histamines or b2-agonists when given as add-on therapy
to corticosteroid-treated asthmatics.65,66 The clinical uses of
ECP are summarized in Table 2.
Factors that affect ECP levels in asthmatics
Age
There is some suggestion that ECP appears to be more
sensitive to changes in asthma severity in adolescents thanin pre-pubertal children.56 However, these ﬁndings need to
be conﬁrmed by a more rigorously designed study. A study by
King et al.67 suggested that serum ECP does not appear to be
raised in elderly asthmatic patients, but his study was based
on well community-living older persons and it did not
measure the severity of asthma in its subjects.
Smoking
Sputum ECP in adult asthmatics who smoke is signiﬁcantly
higher than in non-smoking asthmatics.51 Moreover, inhaled
budesonide treatment reduces serum ECP and improves lung
function in non-smoking asthmatics but not in smoking
asthmatics.68 This is expected as smoking is well known to
cause chronic persistent inﬂammation of the airways.
Hence, the smoking history of subjects should be considered
when conducting ECP research or interpreting ECP results.
Circadian rhythm and seasonal variation
Wolthers and Heuck69 reported circadian rhythm variations
in serum ECP in children. They found that serum ECP levels
reached a trough at 8.00 a.m. but climbed as the day
progressed till the late evening and early morning, reaching
a peak at 6.00 a.m. However, this circadian ﬂuctuation is
negligible when one considers that the range of ECP
ﬂuctuation in normal subjects was between 3.970.7 and
16.373.5 mg/L (mean7SEM), and serum ECP in asthmatics is
often raised above 20 mg/L. Serum ECP in non-atopic
children aged 11–16 yr also exhibited seasonal variations
with serum ECP decreasing from a median value of 14 mg/L
in May to 7 mg/L in November.70 These seasonal variations
are probably due to seasonal environmental inﬂuences
rather than daylight exposure, and the levels are so low
and the range so narrow that it would be insigniﬁcant when
serum ECP levels are used as an inﬂammatory marker of
asthma.
ECP and other inﬂammatory markers of asthma
There are many inﬂammatory markers of asthma currently
being investigated such as nitric oxide and their metabo-
lites, arachidonic acid metabolites such as leukotriene E4
and 8-isoprostane, chemokines such as interleukins, g-
interferon, Th2-speciﬁc macrophage-derived chemokine
and eosinophil chemoattractant, eotaxin. These markers
are being measured with established methods such as
exhaled breath, sputum and urine, as well as novel methods
such as exhaled nasal air and exhaled breath condensate.
There have been no published reports on head-to-head
comparisons of these markers with ECP in asthma assess-
ment or management, mainly because many of them are still
in the early stages of research, with the exception of
exhaled nitric oxide (eNO).71 Yet, the measurement of eNO
remains technically challenging, especially in children
younger than 4 years, because it requires patient coopera-
tion, strict standardized sampling techniques and a sus-
tained minimal exhalation ﬂow rate. On the other hand,
saliva collection requires less patient cooperation and is
independent of exhalation ﬂow rate. Thus, further studies
on the clinical utility of salivary ECP and its correlation with
serum and sputum ECP are worthy endeavors. It is beyond
the scope of this article to discuss other markers of airway
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Table 2 Clinical signiﬁcance of ECP in asthma.
Airway inﬂammation
 ECP correlates with activated eosinophils in bronchial mucosa of asthmatics26
 ECP is more sensitive than blood and sputum blood eosinophils in assessing asthma severity27,28
 Sputum ECP is more sensitive than serum ECP in assessing asthma severity15
 ECP levels appears to reﬂect virus-induced airway inﬂammation in asthma but is not affected by type of virus29–31
Airway hyper-responsiveness
 ECP does not correlate with airway hyper-responsiveness15,33–37
Diagnosis of asthma
 ECP is raised in other atopic diseases (e.g. allergic rhinitis, recurrent wheezing)41–43 and infections (e.g. rhinovirus
infections22,44 and bacterial sinusitis22)
 ECP is not useful as a diagnostic tool for asthma because of its lack of speciﬁcity
Assessment of asthma severity
ECP correlates with asthma severity when measured by
 NHLBI STEP classiﬁcation50,51
 Japanese Society of Allergology criteria16
 PEFR16,51
 FEV150,51
 FEV1/FVC50
 Peripheral blood eosinophil count27
 Sputum eosinophil count16
 Skin prick tests36
A guide to tailing down inhaled corticosteroid therapy54
Assessment of compliance
ECP decreases with treatment with anti-inﬂammatory asthma treatment such as
 Inhaled corticosteroids54,56–59
 Oral corticosteroids57
 Mast cell stabilizers54
 Leukotriene receptor antagonists34,60–62
 Tacrolimus63
 Immunotherapy64
G.C.-H. Koh et al.702inﬂammation measurement but we would like to direct the
reader to relevant review articles for more details.72,73Conclusions
ECP is found in many body ﬂuids but serum and sputum
sampling are the most established to date. It reﬂects
airway inﬂammation and not hyper-responsiveness, and
correlates with asthma severity as measured by symptom
score and spirometry. As ECP is not speciﬁc to asthma, it is
not useful as a diagnostic tool. However, it has shown to be
useful in assessment of compliance to most forms of
anti-inﬂammatory therapies in asthma and in guiding the
tapering of ICS in stabilized asthmatics. The response of ECP
levels, rather than the absolute value, to corticoste
roid therapy in asthma is probably more useful in
guiding management and predicting relapse after acute
exacerbations.
The use ECP in asthma has its limitations. It has been
argued that eosinophils are not the only cells involved in
asthma, although it is recognized that they are key playersin this inﬂammatory airway disease.74 Not all forms of
asthma have an atopic basis so the usefulness of ECP will be
limited to allergic forms of asthma. Further research is
needed before ECP can become a useful marker of airway
inﬂammation to guide asthma therapy. For example, little is
known about the relationship between eosinophils and ECP:
Are the raised levels of ECP in asthmatics due to increased
numbers of eosinophils, increased amounts of stored ECP
within eosinophil granules or increased propensity of
eosinophils to release ECP? We need to determine if ECP
levels differ signiﬁcantly between children, adults and
elderly, and improve and standardize our collection methods
to compare research results meaningfully. We also need to
think beyond using ECP values as a single snapshot tool and
begin using serial measurements to look at trends and see if
they can predict asthma relapse and verify compliance and
response to anti-inﬂammatory therapy. ECP may become
even more useful if combined with other markers of asthma.
ECP has the potential to meet our need for an airway
inﬂammatory biomarker in asthma management but the key
to its success lies in using what we currently know and
translating it from bench to bedside.
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